Financial statements are reported in EUR. Prices converted from USD at today's exchange rate. Tranches and alerts stay in USD. Valuation Year 0 uses FY2025, because CapEx from the last four quarters (10.1% of revenue) is far from the annual statements (26.1%).
BNTX — BioNTech SE
€77.62
+€0.51 (+0.66%)
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus.
Market Cap
€19.24B
Forward P/E
-18.1x
52-Week Range
N/A
BNTX Price History
Revenue vs. Net Income
€2.9B
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
-€293M
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-5.2%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
8.0x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
26.1%
CapEx · FY2025
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+0.6%
Dilution · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
